Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study

MLA

Melinda Váradi, et al. “Efficacy of Immune Checkpoint Inhibitor Therapy for Advanced Urothelial Carcinoma in Real-Life Clinical Practice: Results of a Multicentric, Retrospective Study.” Scientific Reports, vol. 13, no. 1, Oct. 2023, pp. 1–11. EBSCOhost, https://doi.org/10.1038/s41598-023-44103-9.

APA

Melinda Váradi, Orsolya Horváth, Orsolya Módos, Tamás Fazekas, Camilla M. Grunewald, Günter Niegisch, Ulrich Krafft, Viktor Grünwald, Boris Hadaschik, Csilla Olah, Anikó Maráz, Andrea Furka, Miklós Szűcs, Péter Nyirády, & Tibor Szarvas. (2023). Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study. Scientific Reports, 13(1), 1–11. https://doi.org/10.1038/s41598-023-44103-9

Chicago

Melinda Váradi, Orsolya Horváth, Orsolya Módos, Tamás Fazekas, Camilla M. Grunewald, Günter Niegisch, Ulrich Krafft, et al. 2023. “Efficacy of Immune Checkpoint Inhibitor Therapy for Advanced Urothelial Carcinoma in Real-Life Clinical Practice: Results of a Multicentric, Retrospective Study.” Scientific Reports 13 (1): 1–11. doi:10.1038/s41598-023-44103-9.